Clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation
| Current effective version |
|
| Reference number | EMA/CHMP/341363/2014 |
| Published | 16/07/2014 |
| Effective from | 26/12/2014 |
| Keywords | Stroke, systemic embolism, atrial fibrillation, anticoagulant |
| Description | This document provides guidance on the coduct of trials to develop medicinal products in prevention of stroke and systemic embolic events in patients with non-valvular artial fibrillation. |
Document history
Revision 1 Current version | In operation: 26/12/2014–present Published: 11/11/2014 Published: 15/11/2013 Published: 15/08/2012 Published: 07/04/2011 |
Related content
- Directive 2001/83/EC
- Addendum to the note for guidance on antiarrhythmics on atrial fibrillation and atrial flutter
- Antiarrhythmics
- ICH E4 Dose-response information to support drug registration
- ICH E7 Studies in support of special populations: geriatrics
- ICH E9 Statistical principles for clinical trials
- ICH E10 Choice of control group in clinical trials
- Extrapolation of results from clinical studies conducted outside the EU to the EU-population
- Application with 1) Meta-analyses 2) One pivotal study